Andrew Siderowf

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. ncbi request reprint Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome Study
    Andrew Siderowf
    Parkinson s Disease and Movement Disorders Center, Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania 19107, USA
    Mov Disord 27:406-12. 2012
  2. ncbi request reprint [99mTc]TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease
    A Siderowf
    Parkinson Disease and Movement Disorders Center, Department of Neurology, University of Pennsylvania, Philadelphia, USA
    Neurology 64:1716-20. 2005
  3. ncbi request reprint Preclinical diagnosis of Parkinson's disease: are we there yet?
    Andrew Siderowf
    Parkinson s Disease and Movement Disorders Center, Department of Neurology, University of Pennsylvania, 330 South 9th Street, Philadelphia, PA 19107, USA
    Curr Neurol Neurosci Rep 6:295-301. 2006
  4. ncbi request reprint Risk factors for Parkinson's disease and impaired olfaction in relatives of patients with Parkinson's disease
    Andrew Siderowf
    Parkinson s Disease and Movement Disorders Center, Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Mov Disord 22:2249-55. 2007
  5. doi request reprint Premotor Parkinson's disease: clinical features, detection, and prospects for treatment
    Andrew Siderowf
    Parker Family Professor of Neurology Director, Parkinson s Disease and Movement Disorder Center, University of Pennsylvania, USA
    Ann Neurol 64:S139-47. 2008
  6. pmc Genetic influences on cognitive decline in Parkinson's disease
    James F Morley
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvalia, USA
    Mov Disord 27:512-8. 2012
  7. pmc Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease
    William T Hu
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, USA
    Neurology 79:897-905. 2012
  8. pmc Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease
    Alice S Chen-Plotkin
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Ann Neurol 69:655-63. 2011
  9. pmc Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study
    Roy N Alcalay
    Department of Neurology, Columbia University, New York, NY 10032, USA
    Arch Neurol 67:1116-22. 2010
  10. pmc Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease
    Roy N Alcalay
    Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA
    J Clin Exp Neuropsychol 32:775-9. 2010

Detail Information

Publications67

  1. ncbi request reprint Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome Study
    Andrew Siderowf
    Parkinson s Disease and Movement Disorders Center, Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania 19107, USA
    Mov Disord 27:406-12. 2012
    ....
  2. ncbi request reprint [99mTc]TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease
    A Siderowf
    Parkinson Disease and Movement Disorders Center, Department of Neurology, University of Pennsylvania, Philadelphia, USA
    Neurology 64:1716-20. 2005
    ..In vivo imaging of the dopamine transporter with [99mTc]TRODAT-1 (TRODAT) and olfactory testing have both been proposed as potential biomarkers in Parkinson disease (PD)...
  3. ncbi request reprint Preclinical diagnosis of Parkinson's disease: are we there yet?
    Andrew Siderowf
    Parkinson s Disease and Movement Disorders Center, Department of Neurology, University of Pennsylvania, 330 South 9th Street, Philadelphia, PA 19107, USA
    Curr Neurol Neurosci Rep 6:295-301. 2006
    ..The current challenges are to refine these technologies and to determine how they should be employed so that their use is ethical, practical, and meaningful to at-risk individuals...
  4. ncbi request reprint Risk factors for Parkinson's disease and impaired olfaction in relatives of patients with Parkinson's disease
    Andrew Siderowf
    Parkinson s Disease and Movement Disorders Center, Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Mov Disord 22:2249-55. 2007
    ..Further research is warranted to determine whether a history of lower caffeine consumption confers additional risk for the development of PD in hyposmic relatives of PD patients...
  5. doi request reprint Premotor Parkinson's disease: clinical features, detection, and prospects for treatment
    Andrew Siderowf
    Parker Family Professor of Neurology Director, Parkinson s Disease and Movement Disorder Center, University of Pennsylvania, USA
    Ann Neurol 64:S139-47. 2008
    ..Ultimately, the value of screening for PD depends on development of neuroprotective treatments for PD that would create an imperative for early identification and treatment...
  6. pmc Genetic influences on cognitive decline in Parkinson's disease
    James F Morley
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvalia, USA
    Mov Disord 27:512-8. 2012
    ..Clinically, these results suggest that genotyping can provide information about the risk of future cognitive decline for PD patients...
  7. pmc Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease
    William T Hu
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, USA
    Neurology 79:897-905. 2012
    ..Here we aim to determine plasma biomarkers associated with AD in 2 independent cohorts and validate the findings in the multicenter Alzheimer's Disease Neuroimaging Initiative (ADNI)...
  8. pmc Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease
    Alice S Chen-Plotkin
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Ann Neurol 69:655-63. 2011
    ..Most people with Parkinson disease (PD) eventually develop cognitive impairment (CI). However, neither the timing of onset nor the severity of cognitive symptoms can be accurately predicted. We sought plasma-based biomarkers for CI in PD...
  9. pmc Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study
    Roy N Alcalay
    Department of Neurology, Columbia University, New York, NY 10032, USA
    Arch Neurol 67:1116-22. 2010
    ..To assess the frequency and clinical characteristics of carriers of previously identified mutations in 6 genes associated with early-onset Parkinson disease (PD) and provide empirical data that can be used to inform genetic counseling...
  10. pmc Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease
    Roy N Alcalay
    Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA
    J Clin Exp Neuropsychol 32:775-9. 2010
    ..GBA carriers reported more impairment, but MMSE performance did not differ among genetic groups. Detailed neuropsychological testing is required to explore the association between cognitive impairment and GBA mutations...
  11. pmc Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104 3339, USA
    Brain 135:170-80. 2012
    ..In addition, an Alzheimer's disease pattern of brain atrophy may be a preclinical biomarker of cognitive decline in Parkinson's disease...
  12. pmc Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease
    William T Hu
    Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA
    Acta Neuropathol 120:385-99. 2010
    ....
  13. pmc Plasma apolipoprotein A1 as a biomarker for Parkinson disease
    Judy K Qiang
    Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
    Ann Neurol 74:119-27. 2013
    ..To identify plasma-based biomarkers for Parkinson disease (PD) risk...
  14. pmc Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment
    William T Hu
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4283, USA
    Acta Neuropathol 119:669-78. 2010
    ..In summary, our targeted proteomic screen revealed novel CSF biomarkers that can improve the distinction between AD and non-AD cases by established biomarkers alone...
  15. pmc Everyday action impairment in Parkinson's disease dementia
    Tania Giovannetti
    Department of Psychology, Temple University, Philadelphia, Pennsylvania 19122, USA
    J Int Neuropsychol Soc 18:787-98. 2012
    ..jins, 2012, 18, 1-12)...
  16. doi request reprint Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease
    Steven R Schwid
    Department of Neurology, University of Rochester, Rochester, New York, USA
    Mov Disord 25:1801-8. 2010
    ..Melanoma occurrence in our PD patients was greater than predicted compared with the general population and was unrelated to dopaminergic therapy. Clinical surveillance of PD patients for melanoma may be warranted...
  17. pmc Association between cognition and function in patients with Parkinson disease with and without dementia
    Emily Rosenthal
    Department of Neurology, Division of Geriatrics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19107, USA
    Mov Disord 25:1170-6. 2010
    ..87 vs. 0.75, P = 0.0008). Cognition is associated with impairment in ADL function, even in nondemented patients with PD. However, sensitive cognitive assessment measures may be needed to identify these functionally relevant impairments...
  18. pmc Building an integrated neurodegenerative disease database at an academic health center
    Sharon X Xie
    Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Alzheimers Dement 7:e84-93. 2011
    ..These comparative studies rely on powerful database tools to quickly generate data sets that match diverse and complementary criteria set by them...
  19. doi request reprint Cognitive impairment and PD patients' capacity to consent to research
    Jason Karlawish
    University of Pennsylvania, Philadelphia, PA, USA
    Neurology 81:801-7. 2013
    ..To examine how cognitive impairment affects Parkinson disease (PD) patients' research consent capacity...
  20. pmc Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study
    Daniel Weintraub
    University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Neurology 80:176-80. 2013
    ..To determine the frequency and correlates of impulse control and related behavior symptoms in patients with de novo, untreated Parkinson disease (PD) and healthy controls (HCs)...
  21. pmc Odor identification deficits are associated with increased risk of neuropsychiatric complications in patients with Parkinson's disease
    Randolph Stephenson
    Department of Neurology, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania, USA
    Mov Disord 25:2099-104. 2010
    ..These findings suggest that severity of olfactory impairment early in the disease course may be a useful marker for the risk of neuropsychiatric complications of PD...
  22. pmc Treatment disparities in Parkinson's disease
    Nabila Dahodwala
    Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA
    Ann Neurol 66:142-5. 2009
    ..In a group with the same healthcare insurance, disparities in PD treatment exist. Physician and community awareness of these racial differences in PD treatment is the first step in addressing healthcare disparities...
  23. pmc Daytime sleepiness is associated with falls in Parkinson's disease
    Meredith Spindler
    Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA Parkinson s Disease Research, Education, and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, USA
    J Parkinsons Dis 3:387-91. 2013
    ..04) and postural instability/gait dysfunction (OR 1.6 95% CI 1.0-2.4, p = 0.03) in non-depressed patients. In conclusion, non-depressed PD patients are 20% more likely to fall for every one unit increase in the ESS measure of sleepiness. ..
  24. doi request reprint Impairment of script comprehension in Lewy body spectrum disorders
    Rachel G Gross
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Brain Lang 125:330-43. 2013
    ..These findings extend prior work on script processing to patients with Lewy body spectrum disorders and highlight the potential impact of frontal/executive dysfunction on the daily lives of affected patients...
  25. ncbi request reprint Rasagiline improves quality of life in patients with early Parkinson's disease
    Kevin M Biglan
    Department of Neurology, Johns Hopkins University, Baltimore, Maryland 21287, USA
    Mov Disord 21:616-23. 2006
    ..Rasagiline improved QOL compared with placebo. This QOL improvement appears to be accounted for primarily by the symptomatic benefit of rasagiline...
  26. pmc Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores
    Eugenia Mamikonyan
    Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
    Parkinsonism Relat Disord 15:226-31. 2009
    ..We report on the frequency and characteristics of cognitive deficits in PD patients with intact global cognition based on Mini-Mental State Examination (MMSE) performance...
  27. pmc Delayed Parkinson's disease diagnosis among African-Americans: the role of reporting of disability
    Nabila Dahodwala
    Parkinson s Disease Research, Education and Clinical Center, Philadelphia VA Medical Center, Philadelphia, PA, USA
    Neuroepidemiology 36:150-4. 2011
    ..We sought to compare the stage at which African-American and white PD patients present for healthcare, and determine whether perception of disability accounts for racial differences...
  28. pmc Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease
    Rodger J Elble
    Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois, USA
    Mov Disord 25:1082-6. 2010
    ..We found the investigators' level of confidence in these agents had no effect on the time to symptomatic therapy or on the change in UPDRS during 12 months of treatment...
  29. doi request reprint Parkinson's at risk syndrome: can Parkinson's disease be predicted?
    Matthew B Stern
    Penn Comprehensive Neuroscience Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Mov Disord 25:S89-93. 2010
    ..Further, our concept of PD risk will change the nosology of PD as those now considered "at-risk" may ultimately be considered to already have the disease...
  30. pmc Amyotrophic lateral sclerosis-plus syndrome with TAR DNA-binding protein-43 pathology
    Leo F McCluskey
    Department of Neurology, University of Pennsylvania School of Medicine, 330 S 9th St, Philadelphia, PA 19107, USA
    Arch Neurol 66:121-4. 2009
    ....
  31. pmc Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania 19104 2676, USA
    Mov Disord 27:242-7. 2012
    ..Preliminary results suggest that it can be used to support a diagnosis of these disorders, as well as to monitor changes in symptom severity over time...
  32. ncbi request reprint F2 isoprostane levels in plasma and urine do not support increased lipid peroxidation in cognitively impaired Parkinson disease patients
    James Connolly
    Department of Neurology, Parkinson s Disease and Movement Disorders Center, Pennsylvania Hospital, Philadelphia, PA 19107, USA
    Cogn Behav Neurol 21:83-6. 2008
    ..To determine the utility of 8,12-isoprostaneF2alpha-VI (iP), a specific and sensitive index of lipid peroxidation, as a biomarker for dementia in Parkinson disease (PD)...
  33. pmc Can a screening questionnaire accurately identify mild Parkinsonian signs?
    Nabila Dahodwala
    Parkinson s Disease and Movement Disorders Center, Pennsylvania Hospital, 330 South Ninth Street, Philadelphia, PA 19107, USA
    Neuroepidemiology 39:171-5. 2012
    ..Our objective was to assess the ability of a 9-item Parkinson's Disease Screening Questionnaire (PDSQ), which has high sensitivity in the detection of overt Parkinson's disease (PD), to detect MPS...
  34. ncbi request reprint Long-term effects of bilateral subthalamic nucleus stimulation on health-related quality of life in advanced Parkinson's disease
    Andrew Siderowf
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19107, USA
    Mov Disord 21:746-53. 2006
    ..01). In this selected group of patients, many of the short-term gains in HRQL persist beyond 18 months after STN implantation. Benefits in nonmotor aspects of HRQL such as bodily discomfort and stigma appear to be among the most durable...
  35. pmc Design of comprehensive Alzheimer's disease centers to address unmet national needs
    John Q Trojanowski
    Institute on Aging, Philadelphia, PA, USA
    Alzheimers Dement 6:150-5. 2010
    ..The intent of this position paper is to stimulate thinking and foster the development of other or alternative models for a systematic approach to the study of dementia and movement disorders...
  36. pmc Premotor Parkinson's disease: concepts and definitions
    Andrew Siderowf
    Parkinson s Disease and Mov Disord Center, Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Mov Disord 27:608-16. 2012
    ....
  37. pmc Screening questionnaires for parkinsonism: a systematic review
    Nabila Dahodwala
    Department of Neurology, University of Pennsylvania, PA, USA
    Parkinsonism Relat Disord 18:216-24. 2012
    ..However, the performance of these questionnaires varied based on the individual items, study sample, and method of administration. The performance of screening questionnaires in the detection of early or mild parkinsonism was modest...
  38. ncbi request reprint Differences in [99mTc]TRODAT-1 SPECT binding to dopamine transporters in patients with multiple system atrophy and Parkinson's disease
    Randel L Swanson
    Division of Nuclear Medicine, 110 Donner Building, H U P, 3400 Spruce Street, Philadelphia, PA, 19104, USA
    Eur J Nucl Med Mol Imaging 32:302-7. 2005
    ..This study evaluated whether [99mTc]TRODAT-1 binding to the dopamine transporter differentiates MSA from other movement disorders...
  39. ncbi request reprint Clinical trials with rasagiline: evidence for short-term and long-term effects
    Andrew Siderowf
    Parkinson s Disease and Movement Disorders Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Neurology 66:S80-8. 2006
    ....
  40. doi request reprint A longitudinal program for biomarker development in Parkinson's disease: a feasibility study
    Bernard Ravina
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    Mov Disord 24:2081-90. 2009
    ..The PostCEPT cohort and associated studies strongly support the feasibility of the LABS-PD approach of retaining and repurposing clinical trial cohorts to collect longitudinal clinical and biomarker data...
  41. ncbi request reprint Preference-based quality-of-life in patients with Parkinson's disease
    Andrew Siderowf
    Departments of Neurology, University of Pennsylvania School of Medicine, Philadelphia, USA
    Neurology 59:103-8. 2002
    ..Because of this property, they are the appropriate measures of quality of life for cost-effectiveness analysis. Although preference-based scales are widely used, their validity has rarely been tested in specific patient groups...
  42. ncbi request reprint Breaking the news: a survey of ALS patients and their caregivers
    Leo McCluskey
    Department of Neurology, University of Pennsylvania, PA 19107, USA
    Amyotroph Lateral Scler Other Motor Neuron Disord 5:131-5. 2004
    ..Greater adherence to certain attributes of effective communication of bad news may improve the way physicians perform this difficult task...
  43. ncbi request reprint Parkinson's disease: clinical features, epidemiology and genetics
    A Siderowf
    Parkinson s Disease and Movement Disorders Center, University of Pennsylvania, Philadelphia, Pennsylvania 19107, USA
    Neurol Clin 19:565-78, vi. 2001
    ..This article reviews the clinical features, epidemiology and genetics of PD, with emphasis on insights from recent genetic and epidemiological studies...
  44. ncbi request reprint Emergence of complex, involuntary movements after gamma knife radiosurgery for essential tremor
    A Siderowf
    Department of Neurology, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Mov Disord 16:965-7. 2001
    ..This case illustrates the need for long-term follow-up to fully evaluate the potential for complications following radiosurgery...
  45. pmc Racial differences in the diagnosis of Parkinson's disease
    Nabila Dahodwala
    Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Mov Disord 24:1200-5. 2009
    ..Better understanding of the complex biological and social determinants of these disparities is critical to improve PD care...
  46. pmc The organization of narrative discourse in Lewy body spectrum disorder
    Sharon Ash
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4283, USA
    Brain Lang 119:30-41. 2011
    ..These findings are consistent with a model of narrative discourse that includes executive as well as language components and with an impairment of the organizational component of narrative discourse in patients with PDD and DLB...
  47. ncbi request reprint Cognitive impairment in Parkinson's disease and dementia with lewy bodies: a spectrum of disease
    Rachel Goldmann Gross
    Parkinson s Disease and Movement Disorders Center, Department of Neurology, University of Pennsylvania Health System, Philadelphia, PA, USA
    Neurosignals 16:24-34. 2008
    ..These observations suggest that common targets for diagnosis and treatment of these disorders can be identified...
  48. ncbi request reprint Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases
    Hanae Nakashima-Yasuda
    Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, HUP Maloney 3rd Floor, Philadelphia, PA 19104 4283, USA
    Acta Neuropathol 114:221-9. 2007
    ..This study expands the concept of TDP-43 proteinopathies by implicating TDP-43 lesions in mechanisms of neurodegeneration in LB disorders...
  49. pmc Local institutional review board (IRB) review of a multicenter trial: local costs without local context
    Bernard Ravina
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    Ann Neurol 67:258-60. 2010
    ..This may be an opportune time for the National Institute of Neurological Disorders and Stroke (NINDS) to adopt a central review model...
  50. ncbi request reprint Diagnostic accuracy of [99mTc]TRODAT-1 SPECT imaging in early Parkinson's disease
    K L Chou
    Parkinson s Disease and Movement Disorders Center, University of Pennsylvania School of Medicine, Pennsylvania Hospital, 330 South Ninth Street, Philadelphia, PA 19107, USA
    Parkinsonism Relat Disord 10:375-9. 2004
    ..79, specificity 0.92). These findings show that TRODAT imaging can accurately differentiate early PD patients from controls and has the potential to improve the diagnosis of patients with early signs of PD...
  51. pmc Genetic testing and Parkinson disease: assessment of patient knowledge, attitudes, and interest
    Dana Clay Falcone
    Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Genet Couns 20:384-95. 2011
    ..Genetic education and counseling tools to address these needs were developed to provide patients with the ability to make informed and knowledgeable genetic testing decisions...
  52. doi request reprint Premotor Parkinson's disease: clinical features and detection strategies
    Randolph Stephenson
    Parkinson s Disease and Movement Disorders Center, Department of Neurology, University of Pennsylvania, Philadelphia, Pennysylvania 19107, USA
    Mov Disord 24:S665-70. 2009
    ..Current research to evaluate efficient screening methods and to understand the clinical and physiological features of "premotor" PD will lay the foundation for the screening and prevention strategies of the future...
  53. ncbi request reprint Update on Parkinson disease
    Andrew Siderowf
    Parkinson s Disease and Movement Disorders Center, University of Pennsylvania, 330 South 9th Street, Philadelphia, Pennsylvania 19107, USA
    Ann Intern Med 138:651-8. 2003
    ....
  54. pmc CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease
    A Siderowf
    Department of Neurology, 330 South 9th Street, Second Floor, Philadelphia, PA 19107, USA
    Neurology 75:1055-61. 2010
    ..Cognitive decline associated with Parkinson disease (PD) is common and highly disabling. Biomarkers that help identify patients at risk for cognitive decline would be useful additions to the clinical management of the disease...
  55. ncbi request reprint Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trial
    Andrew Siderowf
    Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Mov Disord 17:758-63. 2002
    ..The findings are in agreement with previous reports on interrater reliability...
  56. doi request reprint Piloting the NPF data-driven quality improvement initiative
    Michael S Okun
    National Parkinson Foundation Center of Excellence, University of Florida, Movement Disorders Center, McKnight Brain Institute, Department of Neurology, Gainesville, FL 32611, USA
    Parkinsonism Relat Disord 16:517-21. 2010
    ..To pilot a data-driven quality care program in National Parkinson Foundation (NPF) Centers of Excellence...
  57. pmc Differences in depression symptoms in patients with Alzheimer's and Parkinson's diseases: evidence from the 15-item Geriatric Depression Scale (GDS-15)
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA
    Int J Geriatr Psychiatry 22:1025-30. 2007
    ..Depression occurs frequently in patients with both Alzheimer's disease (AD) and Parkinson's disease (PD), but there has been little comparison of depression symptoms in the two populations...
  58. pmc Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease
    Roy N Alcalay
    Department of Neurology, Columbia University, New York, NY 10032, USA
    Arch Neurol 66:1517-22. 2009
    ....
  59. ncbi request reprint Gastrostomy insertion in ALS patients with low vital capacity: respiratory support and survival
    Susan Gregory
    Penn Neurological Institute, 330 South 9th Street, Philadelphia, PA 19107, USA
    Neurology 58:485-7. 2002
    ..Gastrostomy tubes were successfully placed in all patients. Mean survival was 211 days with most patients (67%) surviving more than 180 days. Forced vital capacity at the time of PEG placement did not predict survival...
  60. ncbi request reprint Interest in predictive testing for Parkinson's disease: impact of neuroprotective therapy
    N Dahodwala
    Department of Neurology, Pennsylvania Hospital, University of Pennsylvania, USA
    Parkinsonism Relat Disord 13:495-9. 2007
    ..001). Interest in predictive testing for PD is moderate in the absence of effective therapy, and goes up significantly when both clinical trial participation and neuroprotective therapy are offered...
  61. pmc Multiple pathologies in a patient with a progressive neurodegenerative syndrome
    T W Liang
    Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    J Neurol Neurosurg Psychiatry 76:252-5. 2005
    ..This case raises the possibility that three distinct neuropathological diagnoses share a common aetiology...
  62. ncbi request reprint Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
    E R Dorsey
    Department of Neurology, University of Rochester Medical Center, 1351 Mt Hope Blvd, Suite 223, Rochester, NY 14620, USA
    Neurology 68:384-6. 2007
    ..The number of individuals with PD over age 50 in these countries was between 4.1 and 4.6 million in 2005 and will double to between 8.7 and 9.3 million by 2030...
  63. pmc Serum urate as a predictor of clinical and radiographic progression in Parkinson disease
    Michael A Schwarzschild
    MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Boston, USA
    Arch Neurol 65:716-23. 2008
    ..To determine whether concentration of serum urate, a purine metabolite and potent antioxidant that has been linked to a reduced risk of Parkinson disease (PD), predicts prognosis in PD...
  64. ncbi request reprint Development of quality of care indicators for Parkinson's disease
    Eric M Cheng
    Parkinson s Disease Research, Education Clinical Center PADRECC, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California 90073, USA
    Mov Disord 19:136-50. 2004
    ..01). An expert panel can reach consensus on a set of highly rated quality indicators for PD care, which can be used to assess quality of PD care and guide the design of quality improvement projects...
  65. ncbi request reprint Progressive supranuclear palsy: Setting the scene for therapeutic trials
    Andrew Siderowf
    Neurology 60:892-3. 2003
  66. pmc Optimal frequency for measuring health care resource utilization in Parkinson's disease using participant recall: the FS-TOO resource utilization substudy
    Patrick D Mauldin
    Department of Clinical Pharmacy and Outcomes Sciences, Medical University of South Carolina, and the Ralph H Johnson VA Medical Center, Charleston, South Carolina 29425, USA
    Clin Ther 30:1553-7. 2008
    ....